Claringbold P[au] - Search Results

Year	Number of Results
1953	2
1954	6
1955	6
1956	1
1957	2
1958	2
1960	2
1961	1
1968	1
1986	2
1987	1
1989	2
1991	1
1992	2
1993	1
1994	1
1997	1
2002	1
2003	1
2004	1
2010	2
2011	1
2012	1
2014	1
2015	2
2016	1
2021	1
2022	1

1

Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.

Kesavan M, Grover P, Lam WS, Claringbold PG, Turner JH. Kesavan M, et al. Among authors: claringbold pg. Endocr Relat Cancer. 2021 Jun 20;28(7):521-527. doi: 10.1530/ERC-21-0082. Endocr Relat Cancer. 2021. PMID: 34010146 Clinical Trial.

2

Why use inbred lines?

BIGGERS JD, CLARINGBOLD PJ. BIGGERS JD, et al. Among authors: claringbold pj. Nature. 1954 Sep 25;174(4430):596-7. doi: 10.1038/174596a0. Nature. 1954. PMID: 13203582 No abstract available.

3

Action of gonadotrophins on the ovary.

EMMENS CW, CLARINGBOLD PJ, LAMOND DR. EMMENS CW, et al. Among authors: claringbold pj. Nature. 1957 Jul 6;180(4575):38-9. doi: 10.1038/180038a0. Nature. 1957. PMID: 13451635 No abstract available.

4

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.

Claringbold PG, Turner JH. Claringbold PG, et al. Neuroendocrinology. 2016;103(5):432-9. doi: 10.1159/000434723. Epub 2015 Jun 10. Neuroendocrinology. 2016. PMID: 26065489 Clinical Trial.

5

A highly sensitive assay for oestrogens.

MARTIN L, CLARINGBOLD PJ. MARTIN L, et al. Among authors: claringbold pj. Nature. 1958 Mar 1;181(4609):620-1. doi: 10.1038/181620b0. Nature. 1958. PMID: 13517238 No abstract available.

6

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.

Claringbold PG, Turner JH. Claringbold PG, et al. Cancer Biother Radiopharm. 2015 Aug;30(6):261-9. doi: 10.1089/cbr.2015.1876. Cancer Biother Radiopharm. 2015. PMID: 26181854 Clinical Trial.

7

Long-term survival and toxicity in patients with neuroendocrine tumors treated with ¹⁷⁷ Lu-octreotate peptide radionuclide therapy.

Kennedy KR, Turner JH, MacDonald WBG, Claringbold PG, Boardman G, Ransom DT. Kennedy KR, et al. Among authors: claringbold pg. Cancer. 2022 Jun 1;128(11):2182-2192. doi: 10.1002/cncr.34191. Epub 2022 Apr 1. Cancer. 2022. PMID: 35363879

8

Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.

Kesavan M, Claringbold PG, Turner JH. Kesavan M, et al. Among authors: claringbold pg. Neuroendocrinology. 2014;99(2):108-17. doi: 10.1159/000362558. Epub 2014 Apr 4. Neuroendocrinology. 2014. PMID: 24714208 Clinical Trial.

9

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Claringbold PG, Brayshaw PA, Price RA, Turner JH. Claringbold PG, et al. Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11. doi: 10.1007/s00259-010-1631-x. Epub 2010 Oct 30. Eur J Nucl Med Mol Imaging. 2011. PMID: 21052661 Clinical Trial.

10

Samarium-153 EDTMP therapy of disseminated skeletal metastasis.

Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG. Turner JH, et al. Among authors: claringbold pg. Eur J Nucl Med. 1989;15(12):784-95. doi: 10.1007/BF00255498. Eur J Nucl Med. 1989. PMID: 2483138

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results